* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download Mannose binding lectin and FccRIIa (CD32
Survey
Document related concepts
Gene therapy wikipedia , lookup
Artificial gene synthesis wikipedia , lookup
Population genetics wikipedia , lookup
Epigenetics of diabetes Type 2 wikipedia , lookup
Genetic code wikipedia , lookup
Public health genomics wikipedia , lookup
Neuronal ceroid lipofuscinosis wikipedia , lookup
Gene therapy of the human retina wikipedia , lookup
Pharmacogenomics wikipedia , lookup
Polymorphism (biology) wikipedia , lookup
Genetic drift wikipedia , lookup
Microevolution wikipedia , lookup
Epigenetics of neurodegenerative diseases wikipedia , lookup
Hardy–Weinberg principle wikipedia , lookup
Transcript
Rheumatology 2001;40:1009– 1012 Mannose binding lectin and FccRIIa (CD32) polymorphism in Spanish systemic lupus erythematosus patients J. Villarreal*, D. Crosdale1,*, W. Ollier1, A. Hajeer1, W. Thomson1, J. Ordi, E. Balada, M. Villardell, L.-S. Teh2 and K. Poulton3 Hospital General Vall d’Hebron, Passieg Vall d’Hebron 119-129, Barcelona, Spain, 1Arthritis and Rheumatism Campaign Epidemiology Unit, School of Epidemiology and Health Sciences, Medical School, University of Manchester, Oxford Road, Manchester M13 9PT, 2Department of Rheumatology, Blackburn Royal Infirmary, Bolton Road, Blackburn BB2 3LR and 3Manchester Institute of Nephrology and Transplantation, Manchester Royal Infirmary, Oxford Road, Manchester M13 9WL, UK Abstract Objective. Mannose binding lectin (MBL) and FccRII (CD32) polymorphisms have both been implicated as candidate susceptibility genes in systemic lupus erythematosus (SLE). The aim of this study was to evaluate the relationship of these polymorphisms with SLE. Methods. We studied a cohort of 125 SLE patients from Barcelona, Spain and 138 geographically matched controls. Sequence-specific primer–polymerase chain reaction (SSP–PCR) amplification was used to determine CD32 and MBL structural polymorphisms. MBL haplotypes were established using sequence-specific oligonucleotide probing techniques. Results. Patients carried the MBL codon 54 mutant allele more frequently than controls wodds ratio (OR) 2.2; 95% confidence interval (CI) 1.2–4.0; P = 0.007x and the haplotype HY W52 W54 W57 was found to be significantly lower in cases compared with controls (OR 0.6; 95% CI 0.4 – 0.9; P = 0.016). Conclusion. The MBL gene codon 54 mutant allele appears to be a risk factor for SLE, whilst haplotypes encoding for high levels of MBL are protective against the disease. Differences between controls and patients were not significant when considering the FccRIIa polymorphisms; similar results were observed for renal affectation. KEY WORDS: MBL, FccRIIa, Polymorphism, SLE. Systemic lupus erythematosus (SLE) is a complex autoimmune disease influenced by both genetic and environmental factors w1, 2x. Homozygosity for a number of complement and immunity-related genes has been implicated in the susceptibility to SLE. These include deficiencies of complement components such as C1q, C2, C4, w3–5x, or mannose binding lectin (MBL) w6–9x and the abnormal distribution of FccRIIa allotypes w10–14x. MBL is an acute-phase serum protein w15x of the innate immune system, which participates in complement activation and the opsonization of antigens. The Submitted 13 June 2000; revised version accepted 13 March 2001. * These authors contributed equally to this work. Correspondence to: D. J. Crosdale, Clinical Sciences Building, Northern General Hospital, Herries Road, Sheffield S5 7AU, UK. protein coding region of the gene consists of four exons, and there are five known polymorphic sites within the MBL gene that are thought to affect the amount of protein in serum and have been associated with SLE. Two are situated within the promoter region of the MBL gene wH or L (G to C) at 2550 and Y or X (G to C) at 2221x w16x. The remaining three polymorphic sites are situated within exon 1 of the MBL gene at codon 52 (Arg to Cys) w17x, codon 54 (Gly to Asp) w18x and codon 57 (Gly to Glu) w16x. A number of MBL alleles exist in linkage together. The codon 52 mutation is only found together with the promoter haplotype HY, whereas codon 54 and 57 mutant alleles are found to exist with LY w17x. Human immunoglobulin Fc receptors (FcR) on leucocytes exhibit considerable structural and functional diversity. Within the groups of receptors for IgG there 1009 ß 2001 British Society for Rheumatology 1010 J. Villarreal et al. are three distinct subgroups; FccRI (CD64), FccRII (CD32), and FccRIII (CD16), each containing several different members. The ‘A’ isoform of FccRII is the only receptor on human phagocytic cells that is capable of significant interaction with IgG2 w19x. Two isoforms of FccRIIa are FccRIIa R and FccRIIa H; these differ by one amino acid at position 131 (Arg to His) which results from a single base substitution. The variant containing histidine at this position (FccRIIa-H131) binds human IgG2, and IgG3, more strongly than the ‘lowaffinity’ isoform containing arginine (FccRIIa-R131) w19x. Fcc receptors play an essential role in the clearance of immune complexes. Impaired clearance and removal of immune complexes by the mononuclear phagocyte system can result in the deposition of immune complexes in organs and tissues. In SLE patients, the FccRIIaR131 allotype of CD32 receptor has been associated with renal disease; it was observed that there is an overrepresentation of FccRIIa-R131 homozygosities in SLE patients with renal involvement, compared with patients homozygous for the FccRIIa-H131 allele w13, 14x. We hypothesized that within our population of Spanish SLE patients there would be an overrepresentation of MBL mutant alleles and FccRIIa alleles compared with controls. There would also be an increase in FccRIIa allele frequency in patients with renal involvement compared with those without. Materials and methods One hundred and twenty-five SLE patients were recruited from the Vall d’Hebron Hospital in Barcelona, Spain. These were compared with an ethnically matched random healthy control population recruited from the same geographical region (n = 137). All patients satisfied the 1982 American College of Rheumatology revised criteria for SLE w20x. The clinical manifestations studied were renal involvement (n = 48), articular affectation (n = 102), cutaneous lesions (n = 90), neurological disease (n = 20), and serositis (n = 45). MBL typing DNA was extracted from ethylene diamine tetraacetic acid (EDTA) blood samples using the DNAce2 MaxiBlood Purification System (Bioline). MBL codon 52, 54 and 57 wild and mutant alleles were detected using sequence-specific primer–polymerase chain reactions (SSP–PCR) as previously described by Crosdale et al. w21x. In total, 1042 bp of the promoter and the majority of exon 1 of the MBL gene were amplified. A 464 bp segment of the gene for human growth hormone was amplified as an internal control for each PCR reaction. SSP–PCR reactions were performed in the presence of 1.5 mM MgCl2, 0.2 mM of each deoxynucleotide, 0.5 mM of each primer, in NH4SO4 buffer (Bioline) with 1 unit BioTaq polymerase and 1 M Betaine. Two microlitres of each PCR product was blotted using a Robbins automatic dot blotter. This was alkaline denatured and fixed on to Hybond N+ Nylon membranes (Amersham). Promoter alleles were determined by sequence-specific oligonucleotide probing (SSOP) of the bound PCR product using biotinylated probes, which were previously described by Madsen et al. w22x. All haplotype combinations were determined by the SSP–PCR and SSOP techniques as described. However, a number of individuals could not be haplotyped using these methods alone due to each sample possessing only structurally encoding wild alleles as determined by SSP– PCR and being positive for X, Y, L and H polymorphisms. In such a situation, it was impossible to determine the cisutrans orientation of the promoter alleles. This was resolved by performing further SSP–PCR reactions with HuL forward primers (59 to 39) and XuY reverse primers as described by Crosdale et al. w21x. A number of samples were cloned and sequenced (MBL gene exon 1 and promoter region) to provide control material for this study. FccRIIa typing Each sample was typed for the presence of FccRIIa-H and FccRIIa-R alleles using the method and primers described by Smyth et al. w23x. Two PCR reactions were performed on each sample, both utilizing a common anti-sense primer located downstream of the HuR polymorphism and one of the two allele-specific primers. A second amplification was also made between the anti-sense primer and a common sense primer situated upstream of the HuR polymorphism as an internal control. The control primers amplified 256 bases of the FccRIIa gene, whilst the HuR-specific reaction amplified 224 bases. Statistical analysis x2 analysis (using Yates’ correction, where applicable) was performed to determine the significance of a frequency difference between the two groups (significance level of 5%). Odds ratios (OR) were calculated for significant associations and expressed with 95% confidence intervals (CI). An OR was considered to be significant if the 95% CI did not include 1.0. Results The allele frequencies of the structurally encoding MBL gene and promoter polymorphisms are summarized in Table 1. There was a significant increase in the frequency of 2 550 L allele in the patient group compared with the control population (OR 1.5; 95% CI 1.0–2.1; P = 0.039) and also in the number of patients possessing the codon 54 mutant allele compared with controls (OR 2.2; 95% CI 1.2–4.0; P = 0.007). The codon 57 mutant allele frequency was also increased in the patient group, but this result did not reach statistical significance. MBL haplotype frequencies for both the SLE and control populations are shown in Table 2. The frequency of the HY W52 W54 W57 haplotype MBL and FccRIIa polymorphism in Spanish SLE patients TABLE 1. Allele (promoter variants) and phenotype (structurally encoding) frequencies (%) of MBL polymorphisms in Spanish SLE patients and controls Patients (n = 125) Allele 2550 HuL 2221 XuY Codon 52 Codon 54 Codon 57 H L X Y W M W M W M 30.4 69.6a 14.6 85.4 100 10.8 97.5 30.8b 100 5 Controls (n = 138) 39.1 60.9 18.5 82.5 95.2 12.3 98.6 16.7 100 2.2 W, wild type; M, mutant or dysfunctional allele. a OR 1.5; 95% CI 1.0–2.1; P = 0.039. b OR 2.2; 95% CI 1.2–4.0; P = 0.007. TABLE 2. MBL haplotype frequencies (%) in SLE patients and controls MBL haplotype HY W52 W54 W57 LY W52 W54 W57 LX W52 W54 W57 HY M52 W54 W57 LY W52 M54 W57 LY W52 W54 M57 Patients (n = 125) 23.3a 40.4 14.2 5.4 14.2 2.1 Controls (n = 138) 32.9 32.2 18.5 6.2 9.1 1.1 OR 0.6; 95% CI 0.4–0.9; P = 0.016. a was significantly decreased in the patient population (23.3%) compared with the control group (32.9%) (OR 0.6; 95% CI 0.4–0.9; P = 0.016). Haplotypes containing structurally encoding mutant alleles were generally of increased frequency in the SLE population, compared with controls. With regard to FccRIIa, no differences were found between patients (H = 41.3%, R = 58.7%) and controls (H = 42.3%, R = 57.7%). An increased genotype frequency of RuR homozygotes was seen in SLE patients with renal involvement (32.7%) compared with those without renal involvement (22.1%). There was also an increase in the R allele frequency in those patients with renal involvement (63.3%) compared with those without (55.8%). However, both of these findings failed to reach statistical significance. Similar results were observed when considering cutaneous affectation, neurological disorders, arthritis or serositis. Possession of both FccRIIa-R131 and any structurally encoding MBL mutant allele was increased within the SLE population (35.3%) compared with controls (25.0%). Possession of MBL codon 54 mutant alleles together with FccRIIa-R131 alleles also showed an overall increase from 14.0% in the control group to 23.2% in the patients. Both of these differences, however, failed to reach statistical significance. 1011 Discussion Previous studies have shown MBL gene mutations at codons 54 and 57 as being additive risk factors for susceptibility to SLE in different populations w6–9x. In this study we found an increased phenotypic frequency of codon 54 and 57 mutant alleles in SLE patients compared with controls. Nevertheless, the increase observed for codon 57 mutant alleles was not sufficiently high within this sample size to reach significance, which may reflect the rarity of the codon 57 mutant allele in populations of Spanish descent. The MBL haplotype distribution within our control population was consistent with those of previous studies w22x. Codon 52 mutant alleles were found to be in linkage disequilibrium with HY promoter polymorphisms and both codon 54 and 57 mutant alleles carried only LY promoter alleles on their haplotypes. We hypothesized that MBL haplotypes encoding for lowlevel production of the protein would be more prevalent within an SLE population compared with an ethnically matched control population. Our results suggest that this is indeed the case. There was an increase in the frequency of the intermediate-level MBL-producing haplotype LY W52 W54 W57 within the SLE population compared with controls and a significant increase in the high-level MBL-producing HY W52 W54 W57 haplotype frequency within the control group. This finding provides evidence that MBL haplotypes encoding for high serum levels of the protein are protective against the development of SLE. The protective nature of the high serum level-producing MBL haplotypes may become more apparent during an acute-phase response when baseline levels of MBL can increase up to 4-fold w24x. A significantly increased number of codon 54 mutant alleles was observed when comparing SLE patients with renal disease (18u90 alleles, 20.0%) with those without (15u150 alleles, 10.0%) (OR 2.3; 95% CI 1.1–4.7; P = 0.029). The codon 54 mutant allele therefore appears to be acting as a susceptibility factor for the development of renal disease in patients with SLE. Heterozygotes for the MBL codon 54 mutation have approximately one-eighth of the serum protein concentration they would have if encoded by wild alleles w18x. This would account for a reduction in immune complex clearance and complement activation in these individuals, which could ultimately lead to increased susceptibility to renal disease in SLE patients. FccRIIa-R131 homozygosity has previously been associated with renal involvement in SLE patients w13x. In this study, we found no differences between RuR homozygosity in SLE patients compared with controls. This result, together with the R allele frequencies that are approximately equal between populations, suggests that there are no differences in IgG2 and IgG3 immune complex clearance between patients and controls and that the FccRIIa-R131 allele is not a susceptibility factor to the development of SLE. However, a 10% increase in FccRIIa-R131 homozygosity was observed 1012 J. Villarreal et al. in patients with renal disease. This finding, although not significant, suggests decreased levels of IgG2 and IgG3 immune complex clearance in patients with renal disease. A lack of immune complex clearance could result in their accumulation within the blood, especially within densely packed capillary areas such as the kidneys, possibly resulting in the development or onset of renal disease. We analysed our data to look for any differences in the frequencies of both FccRIIa and MBL structural mutant alleles between the SLE population and controls. Increases were seen in the frequencies of both codon 54 mutant and FccRIIa-R131 alleles in the SLE population. These results approached statistical significance and therefore suggest that within our SLE population there is a trend towards impaired immune complex clearance when compared with the control group. This impaired immune complex clearance may, together with a number of other additive factors such as early complement component deficiencies, contribute to disease susceptibility. 11. 12. 13. 14. 15. 16. References 1. Deapen D, Escalante A, Weinrib L et al. A revised estimate of twin concordance in systemic lupus erythematosus. Arthritis Rheum 1992;35:311–8. 2. Winchester RJ, Nunez-Roldan A. Some genetic aspects of systemic lupus erythematosus. Arthritis Rheum 1982; 25:833–7. 3. Walport MJ. Complement deficiency and disease. Br J Rheumatol 1993;32:269–73. 4. Lachmann PJ. New aspects in inherited complement deficiency. In: Chapel HM, Levinsky RJ, Webster ADB, eds. Progress in immune deficiency. III: Proceedings of a meeting of the European group for immunodeficiencies. London: Royal Society of Medicine Services, 1991. 5. Moulds JM, Krych M, Holers VM, Liszewski MK, Atkinson JP. Genetics of the complement system and rheumatic diseases. Rheum Dis Clin North Am 1992; 18:893–914. 6. Davies E, Snowden N, Hillarby C et al. Mannose-binding protein gene polymorphism in systemic lupus erythematosus. Arthritis Rheum 1995;38:110–4. 7. Davies E, Teh L-S, Ordi-Ros J, Snowden N et al. A dysfunctional allele of the mannose binding protein gene associates with SLE in a Spanish population. J Rheumatol 1997;24:485–8. 8. Sullivan K, Wooten C, Goldman D, Petri M. Mannosebinding protein genetic polymorphisms in black patients with SLE. Arthritis Rheum 1996;39:2046–51. 9. Lau YL, Low CS, Chan SY, Karlberg J, Turner MW. Mannose-binding protein in Chinese patients with systemic lupus erythematosus. Arthritis Rheum 1996;39:706–8. 10. Salmon JE, Millard S, Schachter LA, Arnett FC et al. Fc gamma RIIA alleles are heritable risk factors for 17. 18. 19. 20. 21. 22. 23. 24. lupus nephritis in African Americans. J Clin Invest 1996; 97:1348–54. Botto M, Theodoridis E, Thompson EM, Beynon HL et al. Fc gamma RIIa polymorphism in systemic lupus erythematosus (SLE): no association with disease. Clin Exp Immunol 1996;104:264–8. Manger K, Repp R, Spriewald BM, Rascu A et al. Fcgamma receptor IIa polymorphism in Caucasian patients with systemic lupus erythematosus: association with clinical symptoms. Arthritis Rheum 1998;41:1181–9. Duits AJ, Bootsma H, Derksen RHWM et al. Skewed distribution of IgGFc receptor Iia (CD32) polymorphism is associated with renal disease in systemic lupus erythematosus patients. Arthritis Rheum 1995; 39:1832–6. Salmon JE, Ng S, Yoo DH, Kim TH, Kim SY, Song GG. Altered distribution of Fcgamma receptor IIIA alleles in a cohort of Korean patients with lupus nephritis. Arthritis Rheum 1999;42:818–9. Ezekowitz RAB, Day LE, Herman GA. A human mannose-binding protein is an acute phase reactant that shares sequence homology with other vertebrate lectins. J Exp Med 1988;167:1034–46. Lipscombe RJ, Sumiya M, Hill AVS et al. High frequencies in African and non-African populations of independent mutations in the mannose binding protein gene. Hum Mol Gen 1992;1.9:709–15. Madsen HO, Garred P, Kurtzhals JAL et al. A new frequent allele is the missing link in the structural polymorphism of the human mannose-binding protein. Immunogenetics 1994;40:37–44. Sumiya M, Super M, Tabona P et al. Molecular basis of opsonic defect in immunodeficient children. Lancet 1991;337:1569–70. Parren PWHI, Warmerdam PAM, Boeije LCM et al. On the interaction of IgG subclasses with the low affinity fccRIIa (CD32) on human monocytes, neutrophils and platelets: analysis of a functional polymorphism to human IgG2. J Clin Invest 1992;90:1537–46. Tan EN, Cohen AS, Fries JF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271–7. Crosdale DJ, Ollier WER, Thomson W et al. Mannose binding lectin (MBL) genotype distributions with relation to serum levels in UK Caucasoids. Eur J Immunogenet 2000;27:111–7. Madsen HO, Garred P, Thiel S et al. Interplay between promoter and structural gene variants control basal serum level of mannan-binding protein. J Immunol 1995;155:3013–20. Smyth LJC, Snowden N, Carthy D, Papasteriades C, Hajeer A, Ollier WER. FccRIIa polymorphism in systemic lupus erythematosus. Ann Rheum Dis 1997; 56:744–6. Thiel S, Holmskov U, Hviid L, Laursen SB, Jensenious JC. The concentration of the C-type lectin, mannose binding protein, in human plasma increases during an acute phase response. Clin Exp Immunol 1992;90:31–5.